The most common gastrointestinal side effects include: Nausea : Reported in 15-44% of patients (higher rates at Wegovy 2.4 mg), typically most pronounced during dose escalation Diarrhea : Affects approximately 8-30% of users, ranging from mild to moderate severity Vomiting : Occurs in 5-24% of patients (higher rates at Wegovy 2.4 mg), often associated with rapid dose increases Abdominal pain : Experienced by 5-20% of patients, usually described as cramping or discomfort Constipation : Paradoxically affects 3-24% despite the medication's effects on motility Dyspepsia and gastroesophageal reflux : Related to delayed gastric emptying These effects result from semaglutide's pharmacologic action on GLP-1 receptors throughout the gastrointestinal tract
Knop: Bile acid diarrhea is a poorly recognized disorder that may affect as much as 1% of the general population
Gene expression: Your body has a class of proteins that help regulate specific metabolic pathways and genetic interpretations
And Other Nutrients Of Concern Contrasted to the macronutrients protein, carbohydrates and fat that are required in large amounts in the diet for energy metabolism, building structure and other functions in the body, micronutrients are needed in much smaller amounts
Compounded Semaglutide and Tirzepatide are not FDA-approved (more on that below), and a handful of states restrict which protocols are available
- Provides antioxidant benefits